File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: ID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis

TitleID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis
Authors
KeywordsEGFR
Tyrosine kinase inhibitor
Inhibitor of differentiation/DNA binding 1
Drug response
Inflammation-regulated cell death
Issue Date2020
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet
Citation
Cancer Letters, 2020, v. 475, p. 109-118 How to Cite?
AbstractID1 is an oncogenic factor in cancer, but its role in relation to drug sensitivity is unclear. This study aimed to investigate the role of ID1 in drug sensitivity in non-small cell lung cancer (NSCLC). ID1 overexpression in NSCLC cells harboring either EGFR or KRAS mutation was performed and the sensitivity of NSCLC to gefitinib (ZD1839) was measured. A murine orthotopic lung carcinoma model with or without stable ID1 overexpression was developed and treated with gefitinib. Transcriptomic and bioinformatics analyses showed that ID1 overexpression promoted inflammation-related cell death but not apoptosis in gefitinib-treated NSCLC cells. ID1 induced necroptosis by triggering activation of RIP1/RIP3/MLKL pathways. Protein kinase array further suggested that ID1 overexpression maintains Akt activity in gefitinib-treated NSCLC cells, which in turn upregulated FLICE-like inhibitory protein to dissociate the caspase-8-RIP1 complex. The association of RIP1 and RIP3 further activated necroptotic cell death in gefitinib-treated NSCLC. In conclusion, ID1 overexpression in NSCLC induced cellular sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors, regardless of the mutational status of NSCLC. The results may provide scientific evidence for optimizing the treatment outcomes of gefitinib for NSCLC patients.
Persistent Identifierhttp://hdl.handle.net/10722/282259
ISSN
2023 Impact Factor: 9.1
2023 SCImago Journal Rankings: 2.595
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTan, H-Y-
dc.contributor.authorWang, N-
dc.contributor.authorChan, Y-T-
dc.contributor.authorZHANG, C-
dc.contributor.authorGUO, W-
dc.contributor.authorCHEN, F-
dc.contributor.authorZhong, Z-
dc.contributor.authorLi, S-
dc.contributor.authorFeng, Y-
dc.date.accessioned2020-05-05T14:32:49Z-
dc.date.available2020-05-05T14:32:49Z-
dc.date.issued2020-
dc.identifier.citationCancer Letters, 2020, v. 475, p. 109-118-
dc.identifier.issn0304-3835-
dc.identifier.urihttp://hdl.handle.net/10722/282259-
dc.description.abstractID1 is an oncogenic factor in cancer, but its role in relation to drug sensitivity is unclear. This study aimed to investigate the role of ID1 in drug sensitivity in non-small cell lung cancer (NSCLC). ID1 overexpression in NSCLC cells harboring either EGFR or KRAS mutation was performed and the sensitivity of NSCLC to gefitinib (ZD1839) was measured. A murine orthotopic lung carcinoma model with or without stable ID1 overexpression was developed and treated with gefitinib. Transcriptomic and bioinformatics analyses showed that ID1 overexpression promoted inflammation-related cell death but not apoptosis in gefitinib-treated NSCLC cells. ID1 induced necroptosis by triggering activation of RIP1/RIP3/MLKL pathways. Protein kinase array further suggested that ID1 overexpression maintains Akt activity in gefitinib-treated NSCLC cells, which in turn upregulated FLICE-like inhibitory protein to dissociate the caspase-8-RIP1 complex. The association of RIP1 and RIP3 further activated necroptotic cell death in gefitinib-treated NSCLC. In conclusion, ID1 overexpression in NSCLC induced cellular sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors, regardless of the mutational status of NSCLC. The results may provide scientific evidence for optimizing the treatment outcomes of gefitinib for NSCLC patients.-
dc.languageeng-
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet-
dc.relation.ispartofCancer Letters-
dc.subjectEGFR-
dc.subjectTyrosine kinase inhibitor-
dc.subjectInhibitor of differentiation/DNA binding 1-
dc.subjectDrug response-
dc.subjectInflammation-regulated cell death-
dc.titleID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis-
dc.typeArticle-
dc.identifier.emailTan, H-Y: hyhtan@hku.hk-
dc.identifier.emailWang, N: ckwang@hku.hk-
dc.identifier.emailChan, Y-T: ecyt1@hku.hk-
dc.identifier.emailZhong, Z: zfzhong@hku.hk-
dc.identifier.emailLi, S: lishaha@hku.hk-
dc.identifier.emailFeng, Y: yfeng@hku.hk-
dc.identifier.authorityWang, N=rp02075-
dc.identifier.authorityFeng, Y=rp00466-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.canlet.2020.01.025-
dc.identifier.pmid32004572-
dc.identifier.scopuseid_2-s2.0-85079054395-
dc.identifier.hkuros309779-
dc.identifier.volume475-
dc.identifier.spage109-
dc.identifier.epage118-
dc.identifier.isiWOS:000521111300012-
dc.publisher.placeIreland-
dc.identifier.issnl0304-3835-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats